References
- Balfour JA, Lamb HM. Moxifloxacin—a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000;59:115–39.
- Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41:S136–43.
- Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, . Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother 2009;64:188–99.
- Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin. Clin Ther 1999;21: 513–22.
- Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43:83–90.
- Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255–71.
- Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34:25–56.
- Haglund U. Systemic mediators released from the gut in critical illness. Crit Care Med 1993;21:S15–8.
- De Smet J, Boussery K, Colpaert K, De Sutter P, De Paepe P, Decruyenaere J, Van Bocxlaer J. Pharmacokinetics of fluoroquinolones in critical care patients: a bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. J Chromatogr B 2009;877:961–7.
- Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010;99:306–14.
- Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999;43:1508–10.
- Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates—part 2: human trials. Ann Pharmacother 2003;37:1478–88.
- Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, . Pharmacodynamics of levofloxacin—a new paradigm for early clinical trials. JAMA 1998;279:125–9.
- Craig WA. Does the dose matter? Clin Infect Dis 2001;33: S233–7.
- Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999;58:29–36.
- Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, . A critical review of the fluoroquinolones—focus on respiratory tract infections. Drugs 2002;62:13–59.
- Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50:99–110.
- Dumoulin A, Janssen A, De Waele JJ, Decruyenaere J, Hoste EA. Epidemiology of hyperfiltration in ICU patients. Intensive Care Med 2010;36:S140.
- Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1–16.
- Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001;40:1–9.
- Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010;36:332–9.